Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth

• DOI: 10.1136/jitc-2020-000785
• Publication Date: 2020-06-18T05:55:15Z
• Authors: Xin Chen; Norhan Amar; Yuankui Zhu; Chunguang Wang; Chunjiao Xia; Xiaoqing Yang; Dongde Wu; Mingqian Feng
• Keywords: Targeted Therapy

Background Small cell lung cancer (SCLC) accounts for 15% of cancers, and the primary treatment this malignancy is chemotherapy radiotherapy. Delta-like 3 (DLL3) an attractive target SCLC immunotherapy since its expression highly restricted to with a neglectable appearance on normal adult tissues. In current study, we aimed explore efficacy DLL3-targeted via engagement T cell. Methods As proof concept, constructed bispecific antibody chimeric antigen receptor (CAR)-modified cells. vitro in vivo tumor-suppression activity these treatments alone or combination Program Death-1 (PD-1) inhibitory was evaluated. Results studies showed that both DLL3 CAR-T efficiently killed DLL3-positive cells, including native lines H446, H196, H82, artificial A431 cells were forcefully overexpressing DLL3. xenograft mouse models demonstrated suppressed tumor growth, therapy PD-1 dramatically improved antibody, but not Conclusions Our results plus inhibition effective controlling growth.